Product Portfolio

ShilpaBio is leveraging its core capabilities in molecular biology, cancer biology and translational sciences to build a pipeline of affordable biologic therapies.

About Biosimilars

Our Product Portfolio

Product Product Code Therapeutic Area Development Pre-clinical Phase 1 Phase 2 Phase 3 Launch
Adalimumab Biosimilar SBM-01
  • Rheumatology
  • Dermatology
  • Gastroenterology
  • Ophthalmology
 Completed Completed Completed Launched
Aflibercept Biosimilar SBM-02
  • Ophthalmology
 Completed Completed Initiated
Recombinant Human Albumin (NBE) SBM-03
  • Blood Volume Expander
  • Infusion Therapy
 Completed Completed Completed Initiated
FC Fusion Protein Biosimilar SBM-04
  • Rheumatology
 Completed Initiated
Monoclonal Antibodies (mAb) Biosimilar SBM-05
  • Melanoma
  • Hodgkin Disease
  • Carcinoma, Renal Cell
  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Transitional Cell
  • Squamous Cell Carcinoma of Head and Neck
  • Urologic Neoplasms
  • Endometrial Neoplasms
 Completed Initiated
Monoclonal Antibodies (mAb) Biosimilar SBM-06
  • Melanoma
  • Hodgkin Disease
  • Carcinoma, Renal Cell
  • Carcinoma, Non-Small Cell Lung
  • Carcinoma, Transitional Cell
  • Squamous Cell Carcinoma of Head and Neck
  • Urologic Neoplasms
  • Mesothelioma
  • Colorectal Neoplasms
 Initiated
Peptide-ARBM 101 SBM-07
  • Client’s Confidential
 Completed Completed Initiated